Findings from large database important to inform clinical practice
Offers a new option for patients 60 and older with relapsed/refractory disease
What’s coming up at ASH and beyond
Higher type 2 immunity observed in persistent CAR T cells
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
CAR T-cell therapy, bispecifics and antibody drug conjugates have changed disease management
Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel
Advancements lead to a new trial involving autoimmune disease
Two thirds of patients responded to CAR T-cell therapy
Dispelling myths and sharing practical experiences
Autologous anti-CD19 agent produces impressive survival improvements
Advertisement
Advertisement